EP3820451A4 - Dispersion solide comprenant un composé anticancéreux ayant une solubilité et une efficacité améliorées - Google Patents

Dispersion solide comprenant un composé anticancéreux ayant une solubilité et une efficacité améliorées Download PDF

Info

Publication number
EP3820451A4
EP3820451A4 EP19833947.5A EP19833947A EP3820451A4 EP 3820451 A4 EP3820451 A4 EP 3820451A4 EP 19833947 A EP19833947 A EP 19833947A EP 3820451 A4 EP3820451 A4 EP 3820451A4
Authority
EP
European Patent Office
Prior art keywords
efficacy
solid dispersion
improved solubility
anticancer compound
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19833947.5A
Other languages
German (de)
English (en)
Other versions
EP3820451B1 (fr
EP3820451A1 (fr
Inventor
Sonali Sandip BHARATE
Vikas Kumar
Mubashir Javed MINTOO
Dilip Manikrao Mondhe
Sandip Bibishan BHARATE
Ram Vishwakarma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP3820451A1 publication Critical patent/EP3820451A1/fr
Publication of EP3820451A4 publication Critical patent/EP3820451A4/fr
Application granted granted Critical
Publication of EP3820451B1 publication Critical patent/EP3820451B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19833947.5A 2018-07-13 2019-06-14 Dispersion solide comprenant un composé anticancéreux ayant une solubilité et une efficacité améliorées Active EP3820451B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811026240 2018-07-13
PCT/IN2019/050454 WO2020012498A1 (fr) 2018-07-13 2019-06-14 Dispersion solide comprenant un composé anticancéreux ayant une solubilité et une efficacité améliorées

Publications (3)

Publication Number Publication Date
EP3820451A1 EP3820451A1 (fr) 2021-05-19
EP3820451A4 true EP3820451A4 (fr) 2022-04-06
EP3820451B1 EP3820451B1 (fr) 2024-07-24

Family

ID=69142615

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19833947.5A Active EP3820451B1 (fr) 2018-07-13 2019-06-14 Dispersion solide comprenant un composé anticancéreux ayant une solubilité et une efficacité améliorées

Country Status (4)

Country Link
US (1) US12036214B2 (fr)
EP (1) EP3820451B1 (fr)
CA (1) CA3099901C (fr)
WO (1) WO2020012498A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145138A1 (fr) * 2015-03-10 2016-09-15 Shionogi Inc. Dispersions solides
WO2018013693A1 (fr) * 2016-07-13 2018-01-18 Celgene Corporation Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1142C (de) 1877-11-08 S. Weigert & Dr. M. weigert in Berlin Einrichtung an Webschützen, um die von der Spule ablaufenden Einschlagfäden gedreht oder gezwirnt in das Gewebe einzutragen
PL1663217T3 (pl) 2003-08-29 2010-12-31 Lifecycle Pharma As Stałe dyspersje zawierające takrolimus
KR101086254B1 (ko) 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
KR100678824B1 (ko) 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
GB0607105D0 (en) 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
WO2014170914A1 (fr) 2013-04-17 2014-10-23 Council Of Scientific And Industrial Research Analogues de rohitukine comme inhibiteurs des kinases dépendantes des cyclines et son procédé de préparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145138A1 (fr) * 2015-03-10 2016-09-15 Shionogi Inc. Dispersions solides
WO2018013693A1 (fr) * 2016-07-13 2018-01-18 Celgene Corporation Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUMAR VIKAS ET AL: "Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 570, 9 September 2019 (2019-09-09), XP085840510, ISSN: 0378-5173, [retrieved on 20190909], DOI: 10.1016/J.IJPHARM.2019.118683 *
See also references of WO2020012498A1 *

Also Published As

Publication number Publication date
CA3099901A1 (fr) 2020-01-16
US20210308116A1 (en) 2021-10-07
EP3820451B1 (fr) 2024-07-24
CA3099901C (fr) 2024-03-19
WO2020012498A1 (fr) 2020-01-16
EP3820451A1 (fr) 2021-05-19
US12036214B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
EP3588898A4 (fr) Défense contre une attaque apt
EP3647338A4 (fr) Composé macromoléculaire, et élément luminescent mettant en oeuvre celui-ci
EP3634008A4 (fr) Écouteur de sécurité
EP3696922A4 (fr) Connecteur coaxial
EP3782023A4 (fr) Moteur de script et mise en oeuvre
EP3846807A4 (fr) Composés d'imidazoquinoléine et leurs utilisations
EP3838900A4 (fr) Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
EP3703196A4 (fr) Connecteur et ensemble connecteur
EP3604758A4 (fr) Tracteur
EP3604752A4 (fr) Tracteur
EP3666718A4 (fr) Dispositif empêchant une surcharge
EP3666717A4 (fr) Dispositif de prévention de surcharge
EP3966251A4 (fr) Immunothérapies ciblées sur cd33
EP3593416A4 (fr) Ensemble connecteur
EP3638921A4 (fr) Amplificateur de couple
EP3733159A4 (fr) Dispersion de microparticules de lipides
EP3657608A4 (fr) Connecteur et structure de connexion
EP3845592A4 (fr) Dispersion aqueuse
EP3718548A4 (fr) Dispersion solide
EP3655028A4 (fr) Compositions et méthodes contre des infections par p. aeruginosa
EP3419110A4 (fr) Antenne de terminal et terminal
EP3578858A4 (fr) Bouchon d'orifice
EP3564100A4 (fr) Tracteur
EP3780281A4 (fr) Borne à boulon
EP3700549A4 (fr) Lipides à base de céramides à chaîne courte et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/453 20060101ALI20220228BHEP

Ipc: C07D 405/04 20060101ALI20220228BHEP

Ipc: C07D 405/14 20060101ALI20220228BHEP

Ipc: A61K 9/10 20060101AFI20220228BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230323

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230626

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20240306BHEP

Ipc: A61K 31/453 20060101ALI20240306BHEP

Ipc: C07D 405/04 20060101ALI20240306BHEP

Ipc: C07D 405/14 20060101ALI20240306BHEP

Ipc: A61K 9/10 20060101AFI20240306BHEP

INTG Intention to grant announced

Effective date: 20240402

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISHWAKARMA, RAM

Inventor name: BHARATE, SANDIP BIBISHAN

Inventor name: MONDHE, DILIP MANIKRAO

Inventor name: MINTOO, MUBASHIR JAVED

Inventor name: KUMAR, VIKAS

Inventor name: BHARATE, SONALI SANDIP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019055841

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D